Refractory B-ALL

Clinical trials for Refractory B-ALL explained in plain language.

Never miss a new study

Get alerted when new Refractory B-ALL trials appear

Sign up with your email to follow new studies for Refractory B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Antibody-Guided chemotherapy aims to give relapsed leukemia patients a second shot

Disease control Completed

Adults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment have few options. This phase 2 trial tests whether adding epratuzumab, an antibody that attaches to the CD22 protein found on most of these leukemia cells, to standard chemothera…

Matched conditions: REFRACTORY B-ALL

Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control

Last updated Sep 16, 2026 00:00 UTC

Refractory B-ALL

Get alerted when new Refractory B-ALL trials appear

Antibody-Guided chemotherapy aims to give relapsed leukemia patients a second shot